secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pediatrix Medical Group, Inc. (MD)
CIK:        0000893949
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091185
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pediatrix Medical Group Q2 net loss $153M (-$1.84/share); Adjusted EPS $0.34 vs $0.39; CFO transition planned
--------------------------------------------------------------------------------

- Q2 net loss $153M ($1.84 loss per share) vs net income $28.3M ($0.34 EPS) in Q2 2023, driven by $192.9M impairment.
- Adjusted EPS fell to $0.34 from $0.39; Adjusted EBITDA $57.9M vs $59.1M. Revenue $504.3M (+0.7% YoY).
- Company exits office-based and primary/urgent care practices; expects ~$30M annualized EBITDA benefit; guidance reaffirmed $200-220M.
- CFO transition: Kasandra Rossi appointed to succeed Marc Richards effective ~Oct 1, 2024.
- Mary Ann Moore appointed CAO; Dr. Curtis Pickert transitions from COO to Chief Physician Executive (no longer exec officer).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/893949/000095017024091185/0000950170-24-091185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/893949/000095017024091185/md-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer